← Back to home

EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD)

Clinical trials for EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD) explained in plain language.

Never miss a new study

Get alerted when new EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD) trials appear

Sign up with your email to follow new studies for EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Experimental cell therapy offers hope for transplant patients with rare Virus-Driven cancer

Disease control Recruiting now

This study is testing an experimental cell therapy called tabelecleucel for transplant patients who develop a rare cancer caused by Epstein-Barr virus. The treatment uses specially prepared immune cells to target and fight the virus-related cancer in patients who haven't responde…

Matched conditions: EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD)

Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Apr 01, 2026 14:43 UTC

EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD)

Get alerted when new EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD) trials appear

Experimental cell therapy offers hope for transplant patients with rare Virus-Driven cancer